Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma

NCT06325683 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06325683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06325683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Suspended
Start date
November 8, 2024
Completion date
July 15, 2028
Enrollment
184 (estimated)
Sites
325

Conditions

As the registry lists them; a condition with its own page is linked.

progressive glioblastoma, recurrent glioblastoma